General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome - 3rd communication: Effects on respiratory and cardiovascular systems

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 3, 2002, Pages 162-167

  Arisawa, Hirohiko ^a   Fukui, Kenji ^a   Masunaga, Hiroaki ^a  

^a SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

Author keywords

CAS 153504 70 2; Cevimeline; Muscarinic agonist; Sj gren's syndrome; SNI 2011, general pharmacology

Indexed keywords

CEVIMELINE; MUSCARINIC AGENT; SNI 2011;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; CARDIOVASCULAR SYSTEM; DOG; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAM; GUINEA PIG; NONHUMAN; RESPIRATORY SYSTEM; SJOEGREN SYNDROME; XEROSTOMIA;

EID: 0036200134     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299874     Document Type: Article

References (3)

1. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjögren's syndrome
2. (±)-cis-2-methylspiro [1,3-oxathiolane-5,3′-quinuclidine] hydrochloride hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylcholine receptors
3. Long-lasting salivation by a novel muscarinic agonist SNI-2011 in rats and dogs